New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT ( MATHIEU))

Mathieu, Mark P.; Evans, Anne G.; Parexel International Corporation

ISBN 10: 1882615727 / ISBN 13: 9781882615728

Published by Barnett Educational Services / Chi (edition 7), 2005

About this Item

It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Seller Inventory # 1882615727-11-1

Bibliographic Details

• Title: New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT ( MATHIEU))
• Publisher: Barnett Educational Services / Chi (edition 7)
• Publication Date: 2005
• Language: English
• ISBN 10: 1882615727
• ISBN 13: 9781882615728
• Binding: Hardcover
• Edition: 7.
• Condition: Very Good

About this title

Synopsis

Go inside the drug development and FDA regulatory process with today's most authoritative and popular reference on the topic. In its all-new 2008 edition, New Drug Development: A Regulatory Overview addresses the most cutting-edge developments redefining how new drugs are developed and regulated today, including:

* How the FDA Amendments Act of 2007 will affect everything from drug reviews to postmarketing requirements.

* How the CDER's efforts to integrate a culture of drug safety has affected the center's structure and its new drug review and approval processes.

* How CDER's much-anticipated January 2008 transition to the eCTD as the only valid esubmission format will affect the FDA's drug submission and review process.

* How the FDA and industry are already integrating pharmacogenomics, computer simulation, and other emerging technologies to inform key decisions.

* Which drug development strategies are fulfilling their promise and offering optimal returns for industry, given the explosion of accelerated development/approval programs and pilot programs to speed the drug development and review process.


Find out why New Drug Development is pharma/biotech's go-to resource for regulatory, clinical, project management, training, and other drug development disciplines navigating the FDA's drug development approval processes.

Review

This book provides the most comprehensive and up-to-date analysis of FDA's new drug development process available today. I recommend this well-written book for professionals engaged in the drug development and review process. --Biopharm Magazine

This book is superb! It is the single best source of information on the drug regulatory system. --Peter Barton Hutt, Covington & Burling